TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases

Messenger RNA vaccines against SARS-CoV-2

(2021) Eric J. Topol   CELL

Toll‐like receptors in mediating pathogenesis in systemic sclerosis

(2020) L. Frasca et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

First-in-human study of anticancer immunotherapy drug candidate mobilan: safety, pharmacokinetics and pharmacodynamics in prostate cancer patients

(2020) Natalia V. Eremina et al.   Oncotarget

Entolimod as a radiation countermeasure for acute radiation syndrome

(2020) Vijay K. Singh et al.   DRUG DISCOVERY TODAY

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

(2020) Ugur Sahin et al.   NATURE

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

(2020) Edward E. Walsh et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-in-human randomised trial and follow-up study of Plasmodium falciparum blood-stage malaria vaccine BK-SE36 with CpG-ODN(K3)

(2020) Sachiko Ezoe et al.   VACCINE

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018

(2019) Elisabeth M. Hesse et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

HBV vaccination with Fendrix is effective and safe in pre-dialysis CKD population

(2019) Fabrizio Fabrizi et al.   Clinics and Research in Hepatology and Gastroenterology

TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes

(2019) Mariane H. Schleimann et al.   EBioMedicine

Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine

(2019) Thomas C Heineman et al.   CURRENT OPINION IN IMMUNOLOGY

Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response

(2019) Sergio Linares-Fernández et al.   TRENDS IN MOLECULAR MEDICINE

Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson’s Disease

(2018) Valentina Caputi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

mRNA vaccines — a new era in vaccinology

(2018) Norbert Pardi et al.   NATURE REVIEWS DRUG DISCOVERY

Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination

(2018) Elisa Nemes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults

(2018) Randall Hyer et al.   VACCINE

Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial

(2018) Stéphane Pillet et al.   npj Vaccines

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial

(2018) Rhea N. Coler et al.   npj Vaccines

In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma

(2018) Matthew J. Frank et al.   Cancer Discovery

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study

(2018) Antoni Ribas et al.   Cancer Discovery

The immunogenicity and safety of GSK’s recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience

(2017) Caroline Van Den Ende et al.   Expert Review of Vaccines

Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways

(2017) Kai Li et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response

(2017) Darin K. Edwards et al.   Journal of Translational Medicine

The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon

(2017) A R Krarup et al.   Mucosal Immunology

Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy

(2017) V Mett et al.   ONCOGENE

Reactogenicity of Cervarix and Gardasil human papillomavirus (HPV) vaccines in a randomized single blind trial in healthy UK adolescent females

(2017) Tao Haskins-Coulter et al.   Human Vaccines & Immunotherapeutics

Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+T cells

(2016) Shu Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop

(2015) M.E. Beth Smith et al.   ANNALS OF INTERNAL MEDICINE

Interferon regulatory factors: at the crossroads of immunity, metabolism, and disease

(2015) Guang-Nian Zhao et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside

(2015) Burghardt Wittig et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults

(2015) Angelique Kany Kany Luabeya et al.   VACCINE

Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma

(2015) R. L. Sabado et al.   Cancer Immunology Research

Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy

(2015) Kristina Iribarren et al.   OncoImmunology

Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study

(2015) Hubert Kübler et al.   Journal for ImmunoTherapy of Cancer

Toll-Like Receptor Expression in the Blood and Brain of Patients and a Mouse Model of Parkinson's Disease

(2015) J. Drouin-Ouellet et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Vaccine adjuvant uses of poly-IC and derivatives

(2014) Karen AO Martins et al.   Expert Review of Vaccines

Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial

(2014) Hans-Joachim Schmoll et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant

(2014) S. Adams et al.   JOURNAL OF IMMUNOLOGY

Identification of Aim2 as a Sensor for DNA Vaccines

(2014) John J. Suschak et al.   JOURNAL OF IMMUNOLOGY

The mechanism of action of BCG therapy for bladder cancer—a current perspective

(2014) Gil Redelman-Sidi et al.   Nature Reviews Urology

Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer

(2014) Julia Scheiermann et al.   VACCINE

Toll-Like Receptor Signaling Pathways

(2014) Takumi Kawasaki et al.   Frontiers in Immunology

The use of Toll-like receptor 7/8 agonists as vaccine adjuvants

(2013) John P Vasilakos et al.   Expert Review of Vaccines

Triggering of Inflammasome by Aggregated α–Synuclein, an Inflammatory Response in Synucleinopathies

(2013) Gaia Codolo et al.   PLoS One

Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease

(2013) Carmen Noelker et al.   Scientific Reports

Pollinex Quattro: An innovative four injections immunotherapy In allergic rhinitis

(2013) Martin Rosewich et al.   Human Vaccines & Immunotherapeutics

TLR8: the forgotten relative revindicated

(2012) Jorge L Cervantes et al.   Cellular & Molecular Immunology

Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer

(2012) S. Adams et al.   CLINICAL CANCER RESEARCH

Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

(2012) P. Sabbatini et al.   CLINICAL CANCER RESEARCH

Combined Intralesional Bacille Calmette-Guérin (BCG) and Topical Imiquimod for In-transit Melanoma

(2012) Travis B. Kidner et al.   JOURNAL OF IMMUNOTHERAPY

A Double-Blind, Placebo-Controlled, Randomized, Clinical Trial of the TLR-3 Agonist Rintatolimod in Severe Cases of Chronic Fatigue Syndrome

(2012) David R. Strayer et al.   PLoS One

The IkappaB Kinase Family Phosphorylates the Parkinson’s Disease Kinase LRRK2 at Ser935 and Ser910 during Toll-Like Receptor Signaling

(2012) Nicolas Dzamko et al.   PLoS One

Phase 1 Study in Malaria Naïve Adults of BSAM2/Alhydrogel®+CPG 7909, a Blood Stage Vaccine against P. falciparum Malaria

(2012) Ruth D. Ellis et al.   PLoS One

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy

(2012) Erika Vacchelli et al.   OncoImmunology

A Synthetic Adjuvant to Enhance and Expand Immune Responses to Influenza Vaccines

(2010) Rhea N. Coler et al.   PLoS One

Adjuvants for cancer vaccines

(2010) Thomas W. Dubensky et al.   SEMINARS IN IMMUNOLOGY

AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity

(2009) A. M. Didierlaurent et al.   JOURNAL OF IMMUNOLOGY

Ampligen: A potential toll-like 3 receptor adjuvant for immunotherapy of cancer

(2009) B. Jasani et al.   VACCINE

TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines

(2008) Ken J. Ishii et al.   NATURE